GlassScriptPhysician profile
Steven D Hicks
NPI 1750477725
$8,038.12
in general payments reported to CMS, 2019-2025
25 companies · $2,250 in 2025
The $2,250 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $409 · 2022: $986 · 2023: $1,810 · 2024: $2,583 · 2025: $2,250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,623 · Education: $19.07.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,623.35 |
| Education | $19.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,403.12 | 2021-2025 | |
| Pfizer INC. | $1,002.45 | 2023-2025 | |
| Ucb, INC. | $755.99 | 2021-2025 | Briviact, Nayzilam |
| Jazz Pharmaceuticals INC. | $741.83 | 2023-2025 | |
| Neurelis, INC. | $730.97 | 2021-2025 | Valtoco |
| Corium, LLC | $514.76 | 2022-2025 | Azstarys, Azstarys |
| Sk Life Science, INC. | $501.85 | 2021-2025 | |
| Supernus Pharmaceuticals, INC. | $457.36 | 2021-2025 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $331.55 | 2023-2024 | Jornay Pm |
| Catalyst Pharmaceuticals, INC. | $321.63 | 2023-2025 | Fycompa |
| Biohaven Pharmaceutical Holding Company LTD. | $195.42 | 2022 | |
| Livanova USA, INC. | $190.29 | 2022-2025 | Vns Therapy Sentiva Model 1000 Generator, Vns Therapy |
| Biohaven Pharmaceuticals, INC. | $157.35 | 2021 | |
| Abbott Laboratories | $156.06 | 2023 | Cardiomems |
| Ipsen Biopharmaceuticals, INC | $120.11 | 2024-2025 | Dysport |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocodex, INC. | $111.67 | 2023-2025 | Diacomit |
| Eisai INC. | $91.61 | 2022-2023 | |
| Collegium Pharmaceutical, INC. | $69.31 | 2025 | Jornay Pm |
| Teva Pharmaceuticals USA, INC. | $37.39 | 2022-2025 | Ajovy |
| Soleno Therapeutics, INC. | $33.53 | 2025 | Vykat Xr |
| Allergan, INC. | $32.13 | 2021 | |
| Alexion Pharmaceuticals, INC. | $25.25 | 2025 | Koselugo |
| Genzyme Corporation | $21.39 | 2024 | |
| Lilly USA, LLC | $19.29 | 2022 | |
| Sunovion Pharmaceuticals INC. | $15.81 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Hicks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.